|
Major sequelae
|
Low risk (n = 24)
|
Intermediate risk (n = 52)
|
High risk* (n = 26)
|
|---|
|
Recurrent UTI
|
2 (8%)
|
10 (19%)
|
8 (31%)
|
|
Obstructive voiding symptoms
|
1 (4%)
|
12 (23%)
|
15 (58%)
|
|
Persistent hydronephrosis
|
2 (8%)
|
18 (34%)
|
18 (69%)
|
|
Persistent VUR
|
–
|
12 (4%)
|
14 (54%)
|
|
Progressive renal scarring
|
–
|
9 (17%)
|
12 (46%)
|
|
Progressive uremia
|
–
|
1 (2%)
|
12 (46%)
|
|
Valve bladder syndrome
|
–
|
9 (17%)
|
18 (69%)
|
|
Systemic problems**
|
–
|
1 (2%)
|
14 (54%)
|
- *Significant overlap of complications was seen in both intermediate risk and high-risk groups
- **Systemic problems include metabolic acidosis, osteodystrophy, growth failure, etc.
